Skip to main content

Table 2 Cumulative activity of 131I (in GBq [mCi]) depending on the risk classification for the non metastatic patients treated by RAI before 2015 (Group 1) and since 2015 (Group 2)

From: Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

  Group 1 Group 2 P value
n Median Range n Median Range
All risks 46 3.70 [100] 1.11–11.1 [30–300] 38 1.11 [30] 1.11–7.4 [30–200] < 0.001
low-risk 5 3.70 [100] 1.11–3.70 [30–100] 0 N/A N/A < 0.001
intermediate-risk 27 3.70 [100] 1.11–11.1 [30–300] 27 1.11 [30] N/A < 0.001
high-riska 14 5.55 [150] 1.85–9.25 [50–250] 11 2.67 [72] 1.11–7.4 [30–200] < 0.001
  1. N/A not applicable, mCi millicurie, GBq gigabecquerel
  2. a patients with distant metastases are excluded